Phase 2 N=117 Asacol Acute Diverticulitis(DIVA)Study
Diverticulitis
Primary: Global Symptom Score (GSS) at Week 12, Primary Efficacy Population — 7.3; 4.4; 5.9 Scores on a Scale — p=0.3781
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=592 Prevention of Recurrence of Diverticulitis
Diverticulitis
Primary: Percent of Subjects Without Recurrence of Diverticulitis — 62.8; 59.2; 69.1; 67.6 percentage of subjects — p=0.778
Phase 3 N=590 Prevention of Recurrence of Diverticulitis
Diverticulitis
Primary: Percent of Subjects Without Recurrence of Diverticulitis — 62.2; 62.9; 52.7; 64.6 percentage of subjects — p=0.047
N/A N=107 Recurrence Following Nonoperative Management of 1st Episode of Hinchey II Diverticulitis
Diverticulitis
Primary: Primary Study Endpoint — 26; 2 Participants
N/A N=66 Laparoscopic Peritoneal Lavage vs Laparoscopic Sigmoidectomy in Perforated Acute Diverticulitis: a Multicenter Prospective Observational Study (STELLA Study)
Acute Diverticulitis
Primary: Short-term Morbidity — 8; 1 Participants
N/A N=26 Prevalence of Inflammatory Bowel Disease in Patients With Perianal Disease
Inflammatory Bowel Disease · Perianal Fistula · Perianal Abscess
Primary: Prevalence of Inflammation as Diagnosed by Capsule Endoscopy — 6 participants
N/A N=4,561 Chronic Gastrointestinal Sequelae of an Acute Outbreak of Bacterial Gastroenteritis in Walkerton Ontario
Irritable Bowel Syndrome
Primary: Number of Participants With Post Infectious Irritable Bowel Syndrome — 23; 114 participants
Phase 4 N=9 C. Difficile and Ursodiol
Diarrhea
Primary: Percent of Patients With Return Toward a Normal Fecal Bile Acid Pattern — 100 percentage of participants